JAMONY
NAGE

Jacob Asset Management of New York’s Niagen Bioscience NAGE Stock Holding History

Jacob Asset Management of New York’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-84,000
Closed -$828K – 83
2021
Q2 		$828K Buy
84,000
+42,000
+100% +$366K 0.27% 69
2021
Q1 		$392K Buy
42,000
+22,000
+110% +$174K 0.15% 73
2020
Q4 		$96K Buy
+20,000
New +$97.5K 0.07% 66

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $119M AUM 233.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Jacob Asset Management of New York's NAGE Position: Q3 2021 in Review

Jacob Asset Management of New York sold out of Niagen Bioscience (NAGE) in Q3 2021, closing a stake of 84,000 shares — an estimated $828K sold.

Jacob Asset Management of New York first reported a position in NAGE in Q4 2020 and held it in 3 quarters. The position peaked at $828K in Q2 2021. 86 funds tracked by Wall St. Rank hold NAGE as of Q3 2021.

  • Jacob Asset Management of New York reported no remaining Niagen Bioscience position as of Q3 2021 after selling out during the quarter.
  • Jacob Asset Management of New York sold 84,000 Niagen Bioscience shares in Q3 2021, an estimated $828K.
  • Jacob Asset Management of New York first reported a position in Niagen Bioscience in Q4 2020 and held it in 3 quarters.
  • Jacob Asset Management of New York's Niagen Bioscience position peaked at $828K in Q2 2021.
  • 86 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2021.

Based on Jacob Asset Management of New York's 13F filing for Q3 2021, filed 12 Nov 2021.